Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis

Diabetes, Obesity and Metabolism

Volumn 16, Issue 10, 2014, Pages 984-993

  Liakos, A ^a   Karagiannis, T ^a   Athanasiadou, E ^a   Sarigianni, M ^a   Mainou, M ^a   Papatheodorou, K ^a,b   Bekiari, E ^a   Tsapas, Apostolos ^a,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Empagliflozin; Meta analysis; Sodium glucose cotransporter 2 (SGLT2); Systematic review; Type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BLOOD PRESSURE MONITORING; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; RISK;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84912533839     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12307     Document Type: Article

References (44)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
2. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495-502.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Forxiga (Dapagliflozin). Procedure no. EMEA/H/C/002322. European Medicines Agency, London, 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf. Accessed 8 February 2014.
4. U.S. Food and Drug Administration. FDA Approves Invokana to Treat Type 2 Diabetes [news release]. Rockville: U.S. Food and Drug Administration, 2013. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed 8 February 2014.
5. European Medicines Agency. Committe for Medicinal Products for Human Use (CHMP). Assessment Report: Invokana (Canagliflozin). Procedure no. EMEA/H/C/002649. European Medicines Agency, London, 2013. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdf. Accessed 8 February 2014.
6. U.S. Food and Drug Administration. FDA Approves Forxiga to Treat Type 2 Diabetes [news release]. Rockville, MD: U.S. Food and Drug Administration, 2014. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm. Accessed 8 February 2014.
7. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
8. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Summary of Opinion (initial authorization): Empagliflozin (Jardiance). Procedure no. EMEA/CHMP/157961. European Medicines Agency, London, 2014. Available from URL: http://www. ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_- _Initial_authorisation/human/002677/WC500163556.pdf. Accessed 22 March 2014.
9. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-274.
10. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord 2013; 13: 58.
11. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2: e001007.
12. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393.
13. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 457-466.
14. Moher D, Liberati A, TetzlaffJ, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
15. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
20. Barnett AH, Mithal A, Manassie J et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebocontrolled trial. Lancet Diabetes Endocrinol 2014; 2: 369-384.
21. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 721-728.
22. Ferrannini E, Berk A, Hantel S et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013; 36: 4015-4021.
23. Häring HU, Merker L, Seewaldt-Becker E et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404.
24. Häring HU, Merker L, Seewaldt-Becker E et al. Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM). Diabetes 2013; 62: A282.
25. Kadowaki T, Haneda M, Inagaki N et al. Empagliflozin monotherapy for 12 weeks improves glycemic control in Japanese patients with type 2 diabetes (T2DM). Diabetes 2013; 62: A297-298.
26. Kovacs CS, Seshiah V, Swallow R et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2013; 16: 147-158.
27. Roden M, Weng J, Eilbracht J et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-219.
28. Rosenstock J, Seman LJ, Jelaska A et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013; 15: 1154-1160.
29. Rosenstock J, Jelaska A, Wang F et al. Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Can J Diabetes 2013; 37: S32.
30. Tikkanen I, Narko K, Zeller C et al. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Diabetologia 2013; 56: S377.
31. Stack CB, Localio AR, Griswold ME, Goodman SN, Mulrow CD. Handling of rescue and missing data affects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example. Ann Intern Med 2013; 159: 285-288.
32. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
33. Toubro S, Cefalu WT, Xie J et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes. Diabetologia 2012; 55: S313-314.
34. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508.
35. Merovci A, Solis-Herrera C, Daniele G et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-514.
36. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275.
37. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862.
38. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2013; 85: 962-971.
39. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
40. Mithal A, Bernett AH, Manassie J et al. Empagliflozin in patients with type 2 diabetes mellitus and stage 3A, 3B and 4 chronic kidney disease (CKD). Diebetologia 2013; 56: S382.
41. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. Available from URL: http://publications.nice.org.uk/pmg9. Accessed 22 March 2014.
42. Matthews DR, Tsapas A. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diab Vasc Dis Res 2008; 5: 216-218.
43. Ridderstrale M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol 2013; 12: 129.
44. Zinman B, Inzucchi SE, Lachin J et al. Design of the empagliflozin cardiovascular (CV) outcome event trial in type 2 diabetes (T2D). Can J Diabetes 2013; 37: S29-30.